What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “BCD-131 (pegdarbepoetin beta), subcutaneous injection; regimen: once every 4 weeks; therapy duration: 84 weeks”In the company’s words, NCT07119372 on ClinicalTrials.gov
- Tested for
- Anemia, Chronic Kidney Disease, Chronic Kidney Disease Patients on Hemodialysis, Chronic Kidney Disease 5D
- Main trialPhase 3
- “BCD-131 is pegylated darbepoetin beta. This clinical study BCD-131-3 is a randomized, open-label, phase III study of the efficacy and safety of BCD-131 and Mircera used for the treatment of anemia in end-stage chronic kidney disease (CKD) patients on dialysis.”In the company’s words, NCT07119372 on ClinicalTrials.gov
- Other names
- pegylated darbepoetin beta
- Copy of
- Mircera (Hoffman-LA Roche)Tested side by side with the original in NCT03519243, NCT07119372
Other drugs for Anemia
- NTQ5082Nanjing Chia-tai Tianqing Pharmaceutical · Phase 3
- MY008211AWuhan Createrna Science and Technology Co., Ltd · Phase 3
- Pneumococcal Conjugate VaccineSanofi · Phase 3
- AND017Kind Pharmaceuticals LLC · Phase 3
- CrovalimabRoche · Phase 3
- DanicopanAlexion Pharmaceuticals, Inc. · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 12 May 2026 | Study of the Efficacy and Safety of BCD-131 and Mircera® in the Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis | |
| Phase 2Completed | 1 Dec 2018 | Comparative Study of the Efficacy and Safety of BCD-131 and Mircera in Treatment of Anemia in CKD Patients on Dialysis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026